In the News

Antidepressant may prevent severe COVID-19, follow-up study indicates

Professional rater Leonard Imbula holds one of the drugs that will be sent to trial participants for a COVID-19 trial at the Taylor Avenue Building on April 9, 2020. MATT MILLER/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE Study to evaluate antidepressant as potential COVID-19 treatment - Drug fluvoxamine may help prevent life-threatening ‘cytokine storm’ - Staff of the Healthy Mind Lab at Washington University School of Medicine in St. Louis pack medication and medical equipment to be sent to participants in a COVID-19 trial that will help determine whether the psychiatric drug fluvoxamine might help prevent the life-threatening “cytokine storm” that lands many COVID-19 patients in the hospital.
View Content

Low-cost drug lowers risk of hospitalizations, deaths

Leave a Reply

Your email address will not be published. Required fields are marked *